Clinical Trials Browser

Phase 3 × cemiplimab × 30 days × Clear all

NCT05352672 2026-04-22

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Phase 3 Active not recruiting

Melanoma, Neoplasm Metastasis

NCT06585410 2026-04-22

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

Phase 3 Recruiting

Skin Neoplasms

NCT06568172 2026-04-20

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Phase 3 Recruiting

DermatologicHead & NeckSarcoma

Eyelid Squamous Cell Carcinoma

NCT05317858 2026-04-16

LIMITLESS

Phase 3 Recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06931717 2026-04-14

ARCH

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03969004 2026-03-27

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Phase 3 Active not recruiting

415 enrolled 2 FDA

Cutaneous Squamous Cell Carcinoma